154 related articles for article (PubMed ID: 20306156)
21. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
22. JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.
Means RT
Am J Med Sci; 2008 Oct; 336(4):327-9. PubMed ID: 18854675
[TBL] [Abstract][Full Text] [Related]
23. Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera.
Nussenzveig RH; Burjanivova T; Salama ME; Ogilvie NW; Marcinek J; Plank L; Agarwal AM; Perkins SL; Prchal JT
Leuk Lymphoma; 2012 Dec; 53(12):2479-86. PubMed ID: 22642932
[TBL] [Abstract][Full Text] [Related]
24. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
Ishii T; Bruno E; Hoffman R; Xu M
Blood; 2006 Nov; 108(9):3128-34. PubMed ID: 16757685
[TBL] [Abstract][Full Text] [Related]
25. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
27. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
[TBL] [Abstract][Full Text] [Related]
29. [Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera].
Liu D; Zhang PH; Xu ZF; Ma J; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Jia YJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):107-114. PubMed ID: 35381670
[No Abstract] [Full Text] [Related]
30. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
31. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
[TBL] [Abstract][Full Text] [Related]
32. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
Roche-Lestienne C; Andrieux J
Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
[TBL] [Abstract][Full Text] [Related]
33. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
[TBL] [Abstract][Full Text] [Related]
34. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
[TBL] [Abstract][Full Text] [Related]
35. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
36. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
37. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
39. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
40. High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera.
Yeh YM; Chen YL; Cheng HY; Su WC; Chow NH; Chen TY; Ho CL
Am J Clin Pathol; 2010 Aug; 134(2):266-70. PubMed ID: 20660330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]